What Happened?
Shares of clinical research company Fortrea Holdings (NASDAQ: FTRE) jumped 3.3% in the pre-market session after Barclays upgraded the company to Overweight from Equal Weight with a $38 price target.
Barclays analyst Luke Sergott raised the price target from $29, indicating roughly 23% upside from the prior close, in research covered by TipRanks. Sergott highlighted that resilient net new bookings eased prevailing Street worries that the newly separated provider was conceding market share to larger clinical trial rivals. The healthy booking pace confirmed ongoing demand across biopharma sponsors, improving forward visibility into the company’s clinical development pipeline. In notes detailed by StreetInsider, Sergott identified margin recovery potential as study intake stabilizes and Fortrea gradually sheds inherited transition services agreements with former parent Labcorp.
Is now the time to buy Fortrea? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Fortrea’s shares are extremely volatile and have had 51 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 25.3% on the news that the company reported third-quarter financial results that showed stronger-than-expected revenue and an improved outlook for the full year.
For the third quarter, Fortrea announced revenues of $701.3 million, which surpassed analyst estimates. However, its adjusted earnings of $0.12 per share fell short of projections. Despite the mixed bottom-line results, investors appeared to focus on the company's future prospects. Fortrea raised its revenue guidance for the full year to a midpoint of $2.73 billion, up from its previous forecast of $2.65 billion. This improved outlook, along with the strong quarterly sales, signaled confidence in the company's growth, outweighing the earnings miss.
Fortrea is up 34.1% since the beginning of the year, and at $22.54 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Fortrea’s shares at the IPO in June 2023 would now be looking at an investment worth $748.87.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
